The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View mm content recommended for you

EHA 2024 abstracts: What’s hot in multiple myeloma?

By Jennifer Reilly,Jen Wyatt Green

Featured:

María-Victoria Mateos

Meral Beksaç

Vania Tietsche de Moraes Hungria

Jun 10, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Congress, the Multiple Myeloma Hub Steering Committee has provided recommendations for the top abstracts to look out for in multiple myeloma.

Friday, June 14, 2024

Abstract #	Title	Speaker	Time (CEST)
P911	TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B MONUMENTAL-2 STUDY	Emma Searle	18:00 (Poster Session)
P915	LONG-TERM EFFICACY AND SAFETY RESULTS FROM THE PHASE 1/2 MONUMENTAL-1 STUDY OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Leo Rasche	18:00 (Poster Session)
P932	LONG-TERM SURVIVAL AFTER ELRANATAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAGNETISMM-3	Mohamad Mohty	18:00 (Poster Session)

Saturday, June 15, 2024

Abstract #	Title	Speaker	Time (CEST)
S201	DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF MINIMAL RESIDUAL DISEASE IN THE PERSEUS TRIAL	Pieter Sonneveld	11:45–12:00
S202	ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: POST TRANSPLANTATION INTERIM ANALYSIS OF THE RANDOMIZED PHASE III GMMG-HD7 TRIAL	Marc S. Raab	12:00–12:15
S100	PHASE 3 STUDY RESULTS OF ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) VERSUS VRD FOR TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (IMROZ)	Thierry Facon	14:45–15:00
S205	CILTACABTAGENE AUTOLEUCEL ± LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA WITH SUBOPTIMAL RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANT: CARTITUDE-2 COHORT D	Wilfried Roeloffzen	16:30–16:45
S208	IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS (PTS) WITH CLINICAL HIGH-RISK EARLY RELAPSE MULTIPLE MYELOMA (MM) WITHOUT FRONT-LINE (1L) AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): KARMMA-2 COHORT 2B	Xavier Leleu	17:15–17:30

Sunday, June 16, 2024

Abstract #	Title	Speaker	Time (CEST)
LB3440	RESULTS FROM THE RANDOMIZED PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS PMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN REPALPSED/REFRACTORY MULTIPLE MYELOMA	Meletios Dimopoulos	10:00 - 10:15
S210	CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY	Shaji Kumar	11:30 - 11:45
S212	LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE LINKER-MM1 STUDY: DEPTH AND DURABILITY OF RESPONSE AT 14-MONTH MEDIAN FOLLOW-UP	Suzanne Lentzsch	12:00–12:15
S214	RESULTS FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	María-Victoria Mateos	12:30–12:45

EHA 2024 top abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?

To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Mye...

Jun 6, 2023

Dermatological toxicities associated with talquetamab in RRMM

Here, we summarize a retrospective study published by Lery et al. in Journal of the American Ac...

Mar 22, 2024

MagnetisMM-3 trial: Patient-reported outcomes following treatment with elranatamab

Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patie...

Apr 22, 2024

Subscribe to get the best content delivered to your inbox

EHA 2024 abstracts: What’s hot in multiple myeloma?

Friday, June 14, 2024

Saturday, June 15, 2024

Sunday, June 16, 2024

Related articles

Newsletter

Areas of interest